HCV Guidance Panel

Current Chairs

University of Chicago Medical Center

University of California Los Angeles

University of Pennsylvania School of Medicine

University of California

Current Panel Members

Toronto Western Hospital Liver Center

National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health

Ann & Robert H. Lurie Children's Hospital of Chicago
Professor of Pediatrics, Feinberg Northwestern School of Medicine

University of Washington

University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences

Icahn School of Medicine at Mount Sinai

Yale University School of Medicine

Boston University School of Medicine

University of Michigan

San Francisco AIDS Foundation

Coalition on Positive Health Empowerment

Centers for Disease Control and Prevention

Keck Medicine at University of Southern California

University of Pennsylvania

Columbia University Medical Center

Tufts University School of Medicine

Brigham and Women’s Hospital
Harvard Medical School

Emory University School of Medicine

Past Chairs

Massachusetts General Hospital
Co-Chair: 2015-2017
Panel Member: 2013-2014

Baylor University Medical Center (retired)
2013-2015

National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
Co-Chair: 2018-2020
Panel Member: 2016-2017

University of Chicago Medical Center (retired)
2013-2014

Harvard Medical School
Co-Chair: 2015-2018
Panel Member: 2013-2015

Weill Cornell Medical College
Co-Chair: 2018-2020
Panel Member: 2013-2017

National Institutes of Health
2013-2015

Veterans Affairs Long Beach Healthcare System
Co-chair: 2019-2022
Panel member: 2013-2018

Duke University School of Medicine
Durham VA Medical Center
Co-Chair: 2015-2017
Panel Member: 2013-2014

The University of Alabama at Birmingham
2013-2015

The Johns Hopkins University School of Medicine
2013-2015

College of Medicine, Mayo Clinic
Co-Chair: 2015-2018
Panel Member: 2013-2015

Denver Health
Co-chair: 2018-2022
Panel member: 2013-2016

Past Panel Members

Building Equity and Alignment for Impact
2016-2020

Intermountain Medical Center
2013-2016

Johns Hopkins University School of Medicine
10/2015-11/2019

University of Michigan Medical School
2013-2017

Bach and Godofsky, Infectious Diseases
2013-2016

Henry Ford Health System/Division of Hepatology
2016-2022

TREK Therapeutics, PBC
2014-2015

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
2015-2018

Harvard Medical School
Boston Children’s Hospital
2016-2022

Division of Infectious Diseases
Institute of Human Virology/University of Maryland
2013-2016

University of Miami School of Medicine
2013-2016

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
2013-2015

University of California San Francisco
10/2015-11/2019

Harm Reduction Coalition
2013-2017

Rush University Medical Center
2013-2016

Hospital of the University of Pennsylvania
2015-2022

University of California San Diego
2013-2015

Hepatitis and Liver Clinic
University of Washington
2015-2022

University of Cincinnati College of Medicine
2013-2015

The Johns Hopkins University School of Medicine
2013-2015

Treatment Action Group
2015-2018

Jonathan Lax Treatment Center
Philadelphia FIGHT

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
2013-2015

Contributors

Division of Viral Hepatitis
Centers for Disease Control and Prevention

Division of Maternal Fetal Medicine, The Ohio State University

Division of Maternal Fetal Medicine, Massachusetts General Hospital

St. John Health Communications & Consulting

NIH Library
National Institutes of Health

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention

Project Managers

Website Publication and Management

Program Director


Acknowledgement

The International Antiviral Society–USA (IAS–USA) served as the collaborating partner for the HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C from the project’s inception in mid- 2013 through 2015. IAS-USA was responsible for managing the writing panel and the guidance development process. A representative from IAS–USA also served as a co-chair of the HCV Guidance Panel. Due to priorities related to their core mission, IAS-USA elected to end their relationship as collaborating partner on December 31. AASLD and IDSA recognize IAS-USA’s tremendous contribution to the HCV Guidance and the creation and maintenance of www.hcvguidelines.org. Special appreciation is extended to the following individuals for their outstanding service:

  • Michael Saag, MD
  • Donna Jacobsen
  • Cindy Downing
  • Michelle Valderama
  • Jennezel Peneda
  • Rachel Lastra

 

 

 

Top